ASH 2023 | Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the findings of a real-world comparison assessing lenalidomide, bortezomib, and dexamethasone (RVD) vs daratumumab-RVD (D-RVD) in patients with newly diagnosed transplant-eligible multiple myeloma (MM). This analysis included a wider diversity of patients than is seen in many trials, with results consistent across groups. Data suggest that D-RVD confers a progression-free survival (PFS) and overall survival (OS) benefit in patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Novartis, Janssen
Consultancy: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc.
Advisory Committee: TG Therapeutics Inc:
Board of Directors with Stock: Bristol-Myers Squibb Company, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc. Contracted Research: Janssen
